<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05048264</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00108093</org_study_id>
    <nct_id>NCT05048264</nct_id>
  </id_info>
  <brief_title>Effect of Corticosteroid Injections on Blood Glucose</brief_title>
  <acronym>CSI</acronym>
  <official_title>Corticosteroid Injections Administered Under Ultrasound Guidance to Diabetic Patients and the Effect on Blood Glucose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to measure the effect of various corticosteroid formulations&#xD;
      administered to the glenohumeral joint in diabetic patients on resultant blood glucose&#xD;
      readings. In addition, the investigator is looking to quantify the effect of various&#xD;
      corticosteroid formulations administered to the glenohumeral joint via ultrasound-guided&#xD;
      injection on WORC and ASES scores in study patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to measure the effect of various corticosteroid formulations&#xD;
      administered to the glenohumeral joint in diabetic patients on resultant blood glucose&#xD;
      readings. The investigator also aim to quantify the effect of various corticosteroid&#xD;
      formulations administered to the glenohumeral joint via ultrasound-guided injection on WORC&#xD;
      and ASES scores in study patients.&#xD;
&#xD;
      Corticosteroid injections (CSI) are frequently used in orthopedic settings in order to treat&#xD;
      a wide array of orthopedic issues, including osteoarthritis, bursitis, tendinitis, and many&#xD;
      others. The effect of diabetes on the musculoskeletal system and its role in orthopedic&#xD;
      disease has been well-documented. Current evidence demonstrates that corticosteroids, even&#xD;
      when administered through a local musculoskeletal injection, can lead to temporary increases&#xD;
      in blood glucose. Ultrasound guidance was not explicitly used in any of the studies examining&#xD;
      the impact of steroids on blood glucose. The utilization of ultrasound guidance has been&#xD;
      shown to increase accuracy when performing injections into the subacromial space as well as&#xD;
      the glenohumeral joint when compared to palpation/landmark-guided injections.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 27, 2021</start_date>
  <completion_date type="Anticipated">January 11, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 11, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in blood glucose measures</measure>
    <time_frame>Baseline &amp; 2 weeks</time_frame>
    <description>Reported daily glucose measures from baseline to subjects two-week appointment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in patient reported outcomes</measure>
    <time_frame>Baseline, 2 weeks, 6 weeks, 3 months</time_frame>
    <description>Results of patient reported outcomes via WORC scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient reported outcomes</measure>
    <time_frame>Baseline, 2 weeks, 6 weeks, 3 months</time_frame>
    <description>Results of patient reported outcomes via ASES scores</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Steroid Diabetes</condition>
  <condition>Shoulder Pain</condition>
  <arm_group>
    <arm_group_label>Kenalog 40 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Thirty-one subjects will be randomized to this arm. Each subject randomized to this arm will receive one 40 mg corticosteroid injection of Kenalog in the index shoulder.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone 4 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Thirty-one subjects will be randomized to this arm. Each subject randomized to this arm will receive one 4 mg corticosteroid injection of Dexamethasone in the index shoulder.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celestone 6 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Thirty-one subjects will be randomized to this arm. Each subject randomized to this arm will receive one 6 mg corticosteroid injection of Celestone in the index shoulder.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Depo-medrol 40 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Thirty-one subjects will be randomized to this arm. Each subject randomized to this arm will receive one 40 mg corticosteroid injection of Depo-Medrol in the index shoulder.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kenalog 40 MG</intervention_name>
    <description>40 MG/ML Injectable Suspension</description>
    <arm_group_label>Kenalog 40 mg</arm_group_label>
    <other_name>Triamcinolone acetonide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone 4mg</intervention_name>
    <description>4 Mg/mL Injectable Solution</description>
    <arm_group_label>Dexamethasone 4 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celestone</intervention_name>
    <description>6 MG/ML Injectable Suspension</description>
    <arm_group_label>Celestone 6 mg</arm_group_label>
    <other_name>Betamethasone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Depo-medrol</intervention_name>
    <description>40 MG/ML Injectable Suspension</description>
    <arm_group_label>Depo-medrol 40 mg</arm_group_label>
    <other_name>Methylprednisolone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Known diabetic patients ages 40-75 undergoing clinically indicated standard of care&#xD;
             corticosteroid glenohumeral joint injection&#xD;
&#xD;
          -  Ability to perform daily blood glucose testing&#xD;
&#xD;
          -  Can receive and send text messages&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous joint arthroplasty&#xD;
&#xD;
          -  Corticosteroid injection at other sites in the body or in the shoulder within the past&#xD;
             month&#xD;
&#xD;
          -  Systemic corticosteroid within the last month other than asthma inhaler&#xD;
&#xD;
          -  Anyone who are unable to read and/or understand English&#xD;
&#xD;
          -  Pregnant women (self-report)&#xD;
&#xD;
          -  Any clinical reason why any of the four medication options would not be safe or&#xD;
             equally efficacious as the others&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Ceraulo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Duke Sports Medicine Research</last_name>
    <phone>9196848997</phone>
    <email>sportsmed_research@dm.duke.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Duke Sports Science Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Anthony Ceraulo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 8, 2021</study_first_submitted>
  <study_first_submitted_qc>September 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Corticosteroids</keyword>
  <keyword>Injection</keyword>
  <keyword>Shoulder</keyword>
  <keyword>Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shoulder Pain</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

